| SC 13D/A | 2018-02-15 | Kuno Sachiko | Sucampo Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2018-02-15 | Ueno Ryuji | Sucampo Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2018-02-13 | ING GROEP NV | Sucampo Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13G | 2018-02-13 | LSV ASSET MANAGEMENT | Sucampo Pharmaceuticals, Inc. | 2,471,718 | 5.3% | EDGAR |
| SC 13G | 2018-02-08 | BlackRock Inc. | Sucampo Pharmaceuticals, Inc. | 4,121,052 | 8.8% | EDGAR |
| SC 13G/A | 2018-01-12 | Linden Capital L.P. | Sucampo Pharmaceuticals, Inc. | 2,264,288 | 4.6% | EDGAR |
| SC 13D/A | 2018-01-03 | Kuno Sachiko | Sucampo Pharmaceuticals, Inc. | 7,137,344 | 15.3% | EDGAR |
| SC 13D/A | 2018-01-03 | Ueno Ryuji | Sucampo Pharmaceuticals, Inc. | 8,006,585 | 17.2% | EDGAR |
| SC 13G | 2017-12-14 | ING GROEP NV | Sucampo Pharmaceuticals, Inc. | 3,126,299 | 6.7% | EDGAR |
| SC 13G | 2017-12-08 | Linden Capital L.P. | Sucampo Pharmaceuticals, Inc. | 2,489,131 | 5.1% | EDGAR |
| SC 13D/A | 2017-09-28 | Ueno Ryuji | Sucampo Pharmaceuticals, Inc. | 9,080,059 | 19.5% | EDGAR |
| SC 13D/A | 2017-09-28 | Sachiko Kuno Foundation, Inc. | Sucampo Pharmaceuticals, Inc. | 1,215,860 | 2.6% | EDGAR |
| SC 13D/A | 2017-09-28 | Kuno Sachiko | Sucampo Pharmaceuticals, Inc. | 8,353,204 | 17.9% | EDGAR |
| SC 13G/A | 2017-02-14 | S&R Technology Holdings, LLC | Sucampo Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2017-02-08 | BlackRock Inc. | Sucampo Pharmaceuticals, Inc. | 2,160,765 | 4.7% | EDGAR |
| SC 13G | 2017-01-30 | BlackRock Inc. | Sucampo Pharmaceuticals, Inc. | 2,378,710 | 5.2% | EDGAR |
| SC 13D/A | 2016-12-29 | S&R Foundation | Sucampo Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13D | 2016-12-29 | Kuno Sachiko | Sucampo Pharmaceuticals, Inc. | 10,537,627 | 23.0% | EDGAR |
| SC 13D | 2016-12-29 | Ueno Ryuji | Sucampo Pharmaceuticals, Inc. | 10,537,628 | 23.0% | EDGAR |
| SC 13D | 2016-12-29 | Sachiko Kuno Foundation, Inc. | Sucampo Pharmaceuticals, Inc. | 2,400,283 | 5.2% | EDGAR |